| Takeda gives Hematide update | Posted on 29/08/2008 in Pharmaceutical Company Product News Takeda and Affymax have published a clinical development update for Hematide in patients with chemotherapy-induced anaemia.
Both companies have opted to suspend their co-development efforts for the compound in this indication and instead focus all their efforts on the late-stage development of the drug in patients with chronic renal failure-related anaemia.
Takeda noted it has been conducted clinical studies at phase I for Hematide as a treatment for chemotherapy-induced anaemia, but it has opted to suspend its development of the drug in oncology and not enrol any new patients into this trial.
It attributed this decision to the regulatory landscape for erythropoiesis-stimulating agents in oncology in such indications, which it describes as "uncertain".
"Takeda and Affymax are continuing to investigate Hematide for the treatment of anaemia related to chronic renal failure," the companies reaffirmed.
They added that registrational phase III trials for the drug are ongoing, with enrolment for one completed and the others expected to be full by the end of 2008.
In November 2007, Takeda Pharmaceutical and Affymax announced positive phase II trial results for Hematide as a treatment for anaemia in patients with chronic kidney disease and pure red cell aplasia.Other news stories from 29/08/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
